Navigation Links
ESMO survey sheds light on common clinical practice for incompletely resected lung cancer
Date:6/10/2014

Lugano, Switzerland, 10 June 2014 -- A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

Jean Yves Douillard, from the ICO Institut de Cancerologie de l'Ouest Ren Gauducheau, France, Chair of the ESMO Educational Committee, was commenting on a paper published in the journal Lung Cancer[1]. In the study, researchers led by Raffaele Califano of The Christie NHS Foundation Trust, Manchester, UK, surveyed 768 oncologists from 41 European countries about the treatments they offered patients who had "R1 resected" non-small-cell lung cancer[2].

R1 resection is a term used by oncologists to indicate that it is possible to find microscopic evidence of cancer cells remaining after a cancer has been surgically removed.

"We know that incomplete resection, or R1 resection, is associated with a higher risk of relapse but there are currently no strong evidence-based recommendations on how to treat these patients after surgery," Douillard says.

"This study is important since it provides a good overview on how the problem is handled in clinical practice all over Europe by practitioners who treat lung cancer."

Overall, 83% of experts surveyed were medical oncologists --specialists trained to treat cancer using chemotherapy, targeted therapies, immunotherapy and other medications.

Of the respondents, 91.4% prescribed chemotherapy, mostly cisplatin/vinorelbine or cisplatin/gemcitabine. The survey showed that the majority of doctors (85%) discussed with the patient the fact that there was limited clinical evidence to guide treatment options. Almost 50% of participants prescribed radiotherapy, with radiation oncologists most likely to offer this treatment approach.

"Treating physicians clearly believe in what they do, and try to provide the best for their patients," says Douillard. "According to the survey, however, practice is heterogeneous and varies according to the specialty of the treating physicianwhether they are radiation oncologists or medical oncologists. This is why treatment decisions are best made by multidisciplinary teams."

The evidence gathered in this survey is supported by the recommendations of the 2nd ESMO Consensus Conference on Lung Cancer held in 2013, Douillard notes. That group of worldwide recognised experts recommended adjuvant chemotherapy and adjuvant radiation in R1 resected patients.

The authors of the latest paper call for prospective trials to be undertaken to provide stronger evidence to guide post-surgery treatment in this situation. Douillard agrees that such trials would be informative.

"However, trials of adjuvant treatment in R1 resected lung cancer would be very difficult to design and perform, as this is fortunately an infrequent occurrence. R1 resection would also need to be clearly defined in such studies, as it actually represents a quite heterogeneous group."

"Based on evidence from clinical trials in resected patients in whom all tumour cells have been completely removed, there is a rationale for using both chemotherapy and radiotherapy in R1-resected non-small-cell lung cancer," Douillard says.

"As the authors of this survey state, definitive proof would come from a randomised clinical trial, although such studies would be difficult to perform."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Global survey: Climate change now a mainstream part of city planning
2. Success of work team key in defining photonics career success, finds SPIE survey
3. Amazon rainforest survey could improve carbon offset schemes
4. Global survey of urban birds and plants find more diversity than expected
5. Surveys find that despite economic challenges Malagasy fishers support fishing regulations
6. Survey reveals regulatory agencies viewed as unprepared for nanotechnology
7. Survey of supposed deep-sea chemical munitions dump off Southern California
8. National survey finds frog abnormalities are rare
9. First-ever survey of Do-It-Yourself Biology community challenges myths
10. Survey highlights barriers to interdisciplinary environmental science
11. Survey of physicians suggests tablets more useful than smartphones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology: